跳轉至內容
Merck
全部照片(1)

重要文件

GE17-5280-02

nProtein A Sepharose™ 4 Fast Flow

Cytiva 17-5280-02, pack of 200 mL

登入查看組織和合約定價
全部照片(1)

About This Item

分類程式碼代碼:
41106500
NACRES:
NA.56

ligand

native protein A (S. aureus)

包裝

pack of 200 mL

製造商／商標名

Cytiva 17-5280-02

儲存條件

(20% Ehtanol)

基質

4% cross-linked agarose

平均直徑

90 μm (d50v)

工作範圍

3-9

容量

>30 mg binding capacity(human IgG/ml)

適合性

suitable for bioprocess medium

儲存溫度

2-8°C

一般說明

nProtein A Sepharose™ 4 Fast Flow is native protein A coupled to Sepharose™ 4 Fast Flow for the purification of monoclonal and polyclonal antibodies at both laboratory and process scale.

nProtein A Sepharose™ 4 Fast Flow is native protein A coupled to the well established Sepharose™ 4 Fast Flow base matrix. The native protein A ligand is produced by fermenting a selected strain of Staphylococcus aureus. The purified protein is coupled to the cross-linked 4% agarose base matrix by the cyanogen bromide technique, giving a highly stable medium with minimal non-specific adsorption. nProtein A Sepharose™ 4 Fast Flow is manufactured without using animal-derived components.

nProtein A Sepharose™ 4 Fast Flow has nearly twice the total IgG binding capacity of Protein A Sepharose™ CL-4B, and is suitable for recovery and purification of monoclonal antibodies from cell culture at both laboratory and process scale. nProtein A Sepharose™ 4 Fast Flow was developed and tested in co-operation with leading manufacturers of purified monoclonal antibody products, and is used in routine commercial production.

As member of the BioProcess media range, nProtein A Sepharose™ 4 Fast Flow meets industrial demands with security of supply and comprehensive technical and regulatory support.

特點和優勢

  • Replaces Protein A Sepharose™ 4 Fast Flow, the first Cytiva Protein A medium for large-scale purification of antibodies.
  • Used in routine commercial production of monoclonal antibodies
  • Free from animal-derived components.

分析報告

To view the Certificate of Analysis for this product, please visit www.cytiva.com.

法律資訊

Sepharose is a trademark of Cytiva

象形圖

Flame
GHS02

訊號詞

Warning

危險聲明

H226

儲存類別代碼

3 - Flammable liquids

從最近期的版本中選擇一個：

分析證明 (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如果您需要協助，請聯絡 客戶支援

已經擁有該產品？

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Monique G P van der Wijst et al.
Science translational medicine, 13(612), eabh2624-eabh2624 (2021-08-26)
Neutralizing autoantibodies against type I interferons (IFNs) have been found in some patients with critical coronavirus disease 2019 (COVID-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the prevalence of these antibodies, their longitudinal dynamics across
Caleigh Mandel-Brehm et al.
Annals of neurology, 92(2), 279-291 (2022-04-26)
Rapid-onset Obesity with Hypothalamic Dysfunction, Hypoventilation and Autonomic Dysregulation (ROHHAD), is a severe pediatric disorder of uncertain etiology resulting in hypothalamic dysfunction and frequent sudden death. Frequent co-occurrence of neuroblastic tumors have fueled suspicion of an autoimmune paraneoplastic neurological syndrome
Sara E Vazquez et al.
eLife, 9 (2020-05-16)
The identification of autoantigens remains a critical challenge for understanding and treating autoimmune diseases. Autoimmune polyendocrine syndrome type 1 (APS1), a rare monogenic form of autoimmunity, presents as widespread autoimmunity with T and B cell responses to multiple organs. Importantly
Paul Bastard et al.
Science immunology, eabp8966-eabp8966 (2022-07-21)
Life-threatening 'breakthrough' cases of critical COVID-19 are attributed to poor or waning antibody response to the SARS-CoV-2 vaccine in individuals already at risk. Pre-existing autoantibodies (auto-Abs) neutralizing type I IFNs underlie at least 15% of critical COVID-19 pneumonia cases in

文章

Purification Using Protein A-based Chromatography Media

This page shows various purification options for Protein A Sepharose chromatography media and describes typical binding and elution conditions for Protein A Sepharose chromatography media.

Immunoprecipitation Techniques

This page describes immunoprecipitation (immunoaffinity or pull-down techniques).

免疫沉澱技術

本頁說明免疫沉淀（免疫親和或拉取技術）。

條款

Pull-down assays

This page provides information about different pull-down assays for the further isolation of multiprotein complexes to identify their components with products from Cytiva.

牽引測試

本頁提供不同的下拉分析法資訊，以進一步分離多蛋白複合物，鑑定其成分與 Cytiva 的產品。

Protein A-Based Separation with Cytiva Products

Protein A, coupled to Sepharose, binds IgG via its Fc regions, facilitating affinity chromatography purification.

Performing a Purification of IgG Antibodies with Protein G Sepharose® 4 Fast Flow

This page shows how to separate IgG antibodies by affinity chromatography using Protein G Sepharose 4 Fast Flow from Cytiva.

相關內容

Performing a Separation with GE Healthcare Products Based on Protein A

Protein A is derived from a strain of Staphylococcus aureus and contains five regions that bind to the Fc region of IgG. As an affinity ligand, protein A is coupled to Sepharose so that these regions are free to bind IgG.

Performing a Purification of IgG Antibodies with Protein G Sepharose® 4 Fast Flow

This page shows how to separate IgG antibodies by affinity chromatography using Protein G Sepharose 4 Fast Flow from GE Healthcare.

Performing a Purification of IgG Antibodies with Protein G Sepharose® 4 Fast Flow

This page shows how to separate IgG antibodies by affinity chromatography using Protein G Sepharose 4 Fast Flow from GE Healthcare.

我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務